U.S. market Closed. Opens in 10 hours 18 minutes

MLTX | MoonLake Immunotherapeutics Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 42.43 - 44.55
52 Week Range 37.55 - 59.35
Beta 1.07
Implied Volatility 81.70%
IV Rank 50.66%
Day's Volume 142,451
Average Volume 326,455
Shares Outstanding 63,063,900
Market Cap 2,700,711,518
Sector Healthcare
Industry Biotechnology
IPO Date 2020-10-20
Valuation
Profitability
Growth
Health
P/E Ratio -33.72
Forward P/E Ratio N/A
EPS -1.27
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 50
Country Switzerland
Website MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
*Chart delayed
Analyzing fundamentals for MLTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MLTX Fundamentals page.

Watching at MLTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on MLTX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙